Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
$11.7 - $14.98 $56,160 - $71,904
4,800 New
4,800 $59,000
Q2 2023

Aug 08, 2023

SELL
$9.85 - $13.17 $87,665 - $117,213
-8,900 Reduced 24.17%
27,920 $360,000
Q1 2023

May 12, 2023

BUY
$9.44 - $11.88 $347,580 - $437,421
36,820 New
36,820 $361,000
Q2 2022

Aug 09, 2022

SELL
$7.45 - $12.83 $18,684 - $32,177
-2,508 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$9.75 - $14.44 $22,103 - $32,735
2,267 Added 940.66%
2,508 $27,000
Q4 2021

Feb 11, 2022

SELL
$13.17 - $20.94 $120,624 - $191,789
-9,159 Reduced 97.44%
241 $3,000
Q3 2021

Nov 09, 2021

SELL
$9.16 - $19.83 $1,795 - $3,886
-196 Reduced 2.04%
9,400 $180,000
Q2 2021

Aug 12, 2021

BUY
$7.25 - $10.99 $69,571 - $105,460
9,596 New
9,596 $94,000
Q4 2020

Feb 12, 2021

SELL
$3.73 - $5.6 $70,944 - $106,512
-19,020 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$4.32 - $11.7 $82,166 - $222,534
19,020 New
19,020 $82,000
Q2 2020

Aug 13, 2020

SELL
$2.94 - $9.1 $7,211 - $22,322
-2,453 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$2.27 - $6.2 $38,848 - $106,106
-17,114 Reduced 87.46%
2,453 $8,000
Q4 2019

Feb 10, 2020

BUY
$3.46 - $6.93 $67,701 - $135,599
19,567 New
19,567 $111,000
Q3 2019

Nov 12, 2019

SELL
$2.69 - $4.85 $55,139 - $99,415
-20,498 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$3.65 - $7.89 $74,817 - $161,729
20,498 New
20,498 $81,000
Q4 2018

Feb 13, 2019

SELL
$8.14 - $13.28 $86,121 - $140,502
-10,580 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$11.85 - $16.0 $125,373 - $169,280
10,580 New
10,580 $131,000
Q1 2018

May 11, 2018

SELL
$14.65 - $19.9 $20,026 - $27,203
-1,367 Closed
0 $0
Q4 2017

Feb 12, 2018

BUY
$17.3 - $24.08 $23,649 - $32,917
1,367
1,367 $25,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.57B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.